StockNews.AI
ALGS
StockNews.AI
169 days

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

1. ALGS will announce Q4 2024 financial results on March 10, 2025. 2. The company focuses on therapies for liver and viral diseases. 3. ALGS emphasizes its pipeline targeting high unmet medical needs. 4. Forward-looking statements include risks related to drug development. 5. Anticipated financial results could influence investor sentiment.

Earnings
-14.29%Current Return
VS
-1.94%S&P 500
$16.8703/03 08:19 AM EDTEvent Start
$14.4603/04 02:57 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results may indicate progress in development, potentially boosting investor confidence. Historical examples show that positive earnings reports can lead to stock price increases for biotech firms.

How important is it?

The announcement of financial results for a clinical stage company is a significant event that directly impacts investor perception and stock performance. The potential for positive results can drive increased interest and investment in the stock.

Why Short Term?

The immediate financial results announcement has the potential to influence short-term stock movement. A strong earnings report could lead to rapid price adjustments as investors react.

Related Companies

GILDMRNAAMGN
March 03, 2025 08:00 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2024 financial results on Monday, March 10, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. For more information, please visit www.aligos.com or follow us on LinkedIn or X. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed financing, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, and the impact of global events and other macroeconomic conditions on the Aligos business. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. CompanyJordyn TaraziVice President, Investor Relations & Corporate Communications(650) 910-0427jtarazi@Aligos.com

Related News